NCT06833164

ERAP1,2 in Recalcitrant Warts

Serum ERAP1 and ERAP2 Levels in Patients With Recalcitrant Warts

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Benha University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Conditions

• Warts

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	endoplasmic reticulum Aminopeptidase 1 and 2	endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA
DIAGNOSTIC_TEST	endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA	endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA

Timeline

• Start date: 2022-10-01
• Primary completion: 2024-03-20
• Completion: 2024-03-20
• First posted: 2025-02-18
• Last updated: 2025-02-18

Locations

1 site across 1 country: Egypt